Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region

Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region

BackgroundWhether the prognostic nutritional index (PNI), which is suggested to reflect systemic inflammation and nutritional status of patients, could be used as an effective prognostic factor for small-cell lung cancer (SCLC) has not yet been clarified. The purpose of this study was to verify the...

Full description

Bibliographic Details
Main Authors:	Yunjiao Wu, Jing Yang, Xinyi Qiao, Yingjie Li, Rui Zhao, Tie Lin, Xiaoli Li, Meng Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Oncology
Subjects:	prognostic nutritional index (PNI) small cell lung cancer (SCLC) PD-L1/PD-1 inhibitors immune-related adverse events (irAEs) prognostic factor
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1041140/full

Similar Items

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
by: Biagio Ricciuti, MD, et al.
Published: (2020-11-01)

Atezolizumab-induced bilateral anterior uveitis: A case report
by: Tsuyoshi Mito, et al.
Published: (2021-12-01)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
by: Yutaka Takahara, et al.
Published: (2023-09-01)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Pierpaolo Correale, et al.
Published: (2020-08-01)

Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
by: Alice Indini, et al.
Published: (2021-03-01)

Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors
by: Eva Baier, et al.
Published: (2023-04-01)

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
by: Elisa Longhitano, et al.
Published: (2023-03-01)

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
by: Silvia Casagrande, et al.
Published: (2024-04-01)

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
by: Xiaohu Zheng, et al.
Published: (2021-05-01)

Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
by: David Dora, et al.
Published: (2023-02-01)

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
by: Yanfang Zhang, et al.
Published: (2023-03-01)

Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies
by: Yixuan Yu, et al.
Published: (2022-07-01)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
by: Tinglin Yang, et al.
Published: (2023-03-01)

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
by: Samy Hakroush, et al.
Published: (2021-01-01)

An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management
by: Yiyu Cheng, et al.
Published: (2023-06-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation
by: Guacimara Ortega Sanchez, et al.
Published: (2019-11-01)

Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer
by: Yuriko Ueki, et al.
Published: (2020-09-01)

Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
by: Leticia Alserawan, et al.
Published: (2022-10-01)

Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
by: Martina Merli, et al.
Published: (2023-07-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
by: Gunther Glehr, et al.
Published: (2022-09-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
by: Said Dermime, et al.
Published: (2021-10-01)

Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study
by: Frederic Jungbauer, et al.
Published: (2024-02-01)

Immune Checkpoint Inhibitors in Advanced NSCLC: [<sup>18</sup>F]FDG PET/CT as a Troubleshooter in Treatment Response
by: Cristina Ferrari, et al.
Published: (2021-09-01)

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
by: Lærke K. Tolstrup, et al.
Published: (2022-01-01)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
by: Guili Huang, et al.
Published: (2022-11-01)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
by: Taku Fujimura, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
by: Alicia Quilez, MD, et al.
Published: (2020-03-01)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
by: Remo Poto, et al.
Published: (2022-03-01)

Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review
by: Shuting Zhou, et al.
Published: (2023-12-01)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
by: Xiaowei Liu, et al.
Published: (2020-03-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
by: Sae Ohwada, et al.
Published: (2022-06-01)

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
by: Ugochi Ebinama, et al.
Published: (2023-11-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature
by: Yuki Nakagomi, et al.
Published: (2022-05-01)

Immune Checkpoint Inhibitor-Associated Myocarditis
by: Grigorios Chatzantonis, MD, et al.
Published: (2020-04-01)